Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESSOR-2: Mezigdomide + Carfilzomib + Dexamethasone vs Carfilzomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma
jRCT2071230095Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Feb 2024; status: active, not recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071230095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230095.